HMGB1 is an independent predictor of death and heart transplantation in heart failure
- PMID: 22231645
- DOI: 10.1007/s00392-011-0409-x
HMGB1 is an independent predictor of death and heart transplantation in heart failure
Abstract
Background: High-Mobility-Group Box 1 (HMGB1) has been established as an important mediator of myocardial inflammation and associated with progression of heart failure (HF). The aim of this study was to analyze the prognostic value of systemic HMGB1 levels in HF patients with ischemic and non-ischemic cardiomyopathy.
Methods and results: We conducted an analysis (median follow-up time 2.5 years) of HMGB1 plasma concentration in 154 patients with systolic HF and correlated the results with disease severity and prognosis. HMGB1 in HF patients with severe symptoms (NYHA III/IV; 5.35 ng/ml; interquartile range (IQR) = 3.48-8.42 ng/ml) was significantly elevated compared with that in patients with mild symptoms (NYHA I/II; 3.37 ng/ml, IQR = 2.31-5.22 ng/ml, p < 0.0001) and with controls (3.25 ng/ml, IQR = 3.04-3.67 ng/ml, p < 0.0001). HMGB1 levels correlated with other markers of heart failure indicating an association of HMGB1 with disease severity in HF. In a univariate cox regression model for the combined endpoint of death and heart transplantation, HMGB1 proved to be a predictor at cut-off values based on HMGB1 terciles of either 3.4 or 6.1 ng/ml (p = 0.001 and p < 0.0001, respectively). In a multivariate cox regression model, which included NT-proBNP, creatinine, age, NYHA class, white blood cell count, anemia, and age, HMGB1 remained an independent predictor of the combined endpoint (hazard ratio (HR) = 2.48, 95% confidence interval (CI) = 1.06-5.83, p = 0.037 and HR = 2.48, 95% CI = 1.31-4.71, p = 0.005, respectively).
Conclusion: Our findings demonstrate that HMGB1 plasma concentration is elevated in HF and correlates with disease severity and that is an independent predictor of the combined endpoint death and heart transplantation in HF patients.
Similar articles
-
Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure.J Heart Lung Transplant. 2013 May;32(5):533-8. doi: 10.1016/j.healun.2013.01.1048. Epub 2013 Feb 28. J Heart Lung Transplant. 2013. PMID: 23453573
-
[Heart fatty acid binding protein in patients hospitalized because of worsening heart failure. Relation to prognosis of death].Kardiologiia. 2008;48(1):24-9. Kardiologiia. 2008. PMID: 18260992 Russian.
-
Cardiovascular mortality and chronotropic incompetence in systolic heart failure: the importance of a reappraisal of current cut-off criteria.Eur J Heart Fail. 2014 Feb;16(2):201-9. doi: 10.1002/ejhf.36. Epub 2013 Dec 14. Eur J Heart Fail. 2014. PMID: 24464973
-
Clinical use of high mobility group box 1 and the receptor for advanced glycation end products in the prognosis and risk stratification of heart failure: a literature review.Can J Physiol Pharmacol. 2017 Mar;95(3):253-259. doi: 10.1139/cjpp-2016-0299. Epub 2016 Nov 30. Can J Physiol Pharmacol. 2017. PMID: 28092162 Review.
-
Association of circulating blood HMGB1 levels with ischemic stroke: a systematic review and meta-analysis.Neurol Res. 2018 Nov;40(11):907-916. doi: 10.1080/01616412.2018.1497254. Epub 2018 Jul 17. Neurol Res. 2018. PMID: 30015578 Review.
Cited by
-
Specific detection of high mobility group box 1 degradation product with a novel ELISA.Mol Med. 2021 Jun 9;27(1):59. doi: 10.1186/s10020-021-00323-1. Mol Med. 2021. PMID: 34107884 Free PMC article.
-
Intermittent levosimendan treatment in patients with severe congestive heart failure.Clin Res Cardiol. 2013 Jul;102(7):485-93. doi: 10.1007/s00392-013-0554-5. Epub 2013 Mar 17. Clin Res Cardiol. 2013. PMID: 23503714 Clinical Trial.
-
Can the calcium-regulating hormones counteract the detrimental impact of pro-inflammatory damage-associated molecular patterns in the development of heart failure?J Investig Med. 2021 Aug;69(6):1148-1152. doi: 10.1136/jim-2020-001754. Epub 2021 May 5. J Investig Med. 2021. PMID: 33952612 Free PMC article. Review.
-
The Janus face of HMGB1 in heart disease: a necessary update.Cell Mol Life Sci. 2019 Jan;76(2):211-229. doi: 10.1007/s00018-018-2930-9. Epub 2018 Oct 10. Cell Mol Life Sci. 2019. PMID: 30306212 Free PMC article. Review.
-
Immunothrombotic Activity of Damage-Associated Molecular Patterns and Extracellular Vesicles in Secondary Organ Failure Induced by Trauma and Sterile Insults.Front Immunol. 2018 Feb 8;9:190. doi: 10.3389/fimmu.2018.00190. eCollection 2018. Front Immunol. 2018. PMID: 29472928 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous